NIPH Clinical Trials Search

Comparison of Dual-bevel raptor tip needle verses Franseen needle in EUS-TA for pancreatic mass

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	pancreatic mass
Date of first enrollment	01/01/2026
Target sample size	220
Countries of recruitment
Study type	Interventional
Intervention(s)	Patients with pancreatic masses will be randomly assigned in a 1:1 ratio to undergo endoscopic ultrasound-guided tissue acquisition (EUS-TA) using either a dual-beveled raptor tip needle or a Franseen needle, and the outcomes will be compared between the two groups.

Outcome(s)

Primary Outcome	Pathological diagnostic accuracy
Secondary Outcome	1. Technical success rate 2. Difficulty of needle puncture 3. Procedure-related adverse events 4. Macroscopic quantity and quality of the obtained specimen 5. Histological tissue quantity 6. Histological tumor tissue quantity

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	Patients with pancreatic masses identified on imaging studies (CT, MRI, abdominal ultrasonography, or endoscopic ultrasonography) who are scheduled to undergo endoscopic ultrasound-guided tissue acquisition (EUS-TA).
Exclude criteria	1. Patients with a prior pathological diagnosis of pancreatic cancer who undergo endoscopic ultrasound-guided EUS-TA solely for the purpose of comprehensive cancer genomic profiling. 2. Inability to visualize the pancreatic mass by endoscopic ultrasonography due to anatomical reasons. 3. Lesions deemed not amenable to needle puncture based on imaging studies. 4. Bleeding tendency, defined as a prothrombin time-international normalized ratio (PT-INR) > 1.5 or a platelet count < 50000/mm3. 5. Inability to discontinue two or more antithrombotic agents. 6. Age < 18 years. 7. Pregnancy.